open access

Vol 50, No 1 (2016)
Original research articles
Submitted: 2015-05-27
Get Citation

An in vivo model of anti-inflammatory activity of subdural dexamethasone following the spinal cord injury

Jacek M. Kwiecien, Bozena Jarosz, Wendy Oakden, Michal Klapec, Greg J. Stanisz, Kathleen H. Delaney, Edyta Kotlinska-Hasiec, Rafal Janik, Radoslaw Rola, Wojciech Dabrowski
DOI: 10.1016/j.pjnns.2015.10.006
·
Neurol Neurochir Pol 2016;50(1):7-15.

open access

Vol 50, No 1 (2016)
Original research articles
Submitted: 2015-05-27

Abstract

Current therapies to limit the neural tissue destruction following the spinal cord injury are not effective. Our recent studies indicate that the injury to the white matter of the spinal cord results in a severe inflammatory response where macrophages phagocytize damaged myelin and the fluid-filled cavity of injury extends in size with concurrent and irreversible destruction of the surrounding neural tissue over several months. We previously established that a high dose of 4mg/rat of dexamethasone administered for 1 week via subdural infusion remarkably lowers the numbers of infiltrating macrophages leaving large amounts of un-phagocytized myelin debris and therefore inhibits the severity of inflammation and related tissue destruction. But this dose was potently toxic to the rats. In the present study the lower doses of dexamethasone, 0.125–2.0mg, were administered via the subdural infusion for 2 weeks after an epidural balloon crush of the mid-thoracic spinal cord. The spinal cord cross-sections were analyzed histologically. Levels of dexamethasone used in the current study had no systemic toxic effect and limited phagocytosis of myelin debris by macrophages in the lesion cavity. The subdural infusion with 0.125–2.0mg dexamethasone over 2 week period did not eliminate the inflammatory process indicating the need for a longer period of infusion to do so. However, this treatment has probably lead to inhibition of the tissue destruction by the severe, prolonged inflammatory process.

Abstract

Current therapies to limit the neural tissue destruction following the spinal cord injury are not effective. Our recent studies indicate that the injury to the white matter of the spinal cord results in a severe inflammatory response where macrophages phagocytize damaged myelin and the fluid-filled cavity of injury extends in size with concurrent and irreversible destruction of the surrounding neural tissue over several months. We previously established that a high dose of 4mg/rat of dexamethasone administered for 1 week via subdural infusion remarkably lowers the numbers of infiltrating macrophages leaving large amounts of un-phagocytized myelin debris and therefore inhibits the severity of inflammation and related tissue destruction. But this dose was potently toxic to the rats. In the present study the lower doses of dexamethasone, 0.125–2.0mg, were administered via the subdural infusion for 2 weeks after an epidural balloon crush of the mid-thoracic spinal cord. The spinal cord cross-sections were analyzed histologically. Levels of dexamethasone used in the current study had no systemic toxic effect and limited phagocytosis of myelin debris by macrophages in the lesion cavity. The subdural infusion with 0.125–2.0mg dexamethasone over 2 week period did not eliminate the inflammatory process indicating the need for a longer period of infusion to do so. However, this treatment has probably lead to inhibition of the tissue destruction by the severe, prolonged inflammatory process.

Get Citation

Keywords

Spinal cord injury, Phagocytosis of myelin debris, Cavity of CNS injury, Subdural infusion, Inhibition of secondary inflammation

About this article
Title

An in vivo model of anti-inflammatory activity of subdural dexamethasone following the spinal cord injury

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 50, No 1 (2016)

Pages

7-15

DOI

10.1016/j.pjnns.2015.10.006

Bibliographic record

Neurol Neurochir Pol 2016;50(1):7-15.

Keywords

Spinal cord injury
Phagocytosis of myelin debris
Cavity of CNS injury
Subdural infusion
Inhibition of secondary inflammation

Authors

Jacek M. Kwiecien
Bozena Jarosz
Wendy Oakden
Michal Klapec
Greg J. Stanisz
Kathleen H. Delaney
Edyta Kotlinska-Hasiec
Rafal Janik
Radoslaw Rola
Wojciech Dabrowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl